Mersana Therapeutics, Inc. financial data

Symbol
MRSN on Nasdaq
Industry
Pharmaceutical Preparations
Location
840 Memorial Drive, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 265 % -26.2%
Debt-to-equity 2.37K % +577%
Return On Equity -990 % -251%
Return On Assets -40 % +36.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 125M shares +1.86%
Common Stock, Shares, Outstanding 116M shares -4.19%
Entity Public Float 226M USD -37.8%
Common Stock, Value, Issued 12K USD 0%
Weighted Average Number of Shares Outstanding, Basic 123M shares +5.54%
Weighted Average Number of Shares Outstanding, Diluted 123M shares +5.54%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 40.5M USD +9.88%
Research and Development Expense 73M USD -50.8%
General and Administrative Expense 40.8M USD -31.5%
Nonoperating Income (Expense) 4.56M USD -43%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -11.1M USD +73.4%
Income Tax Expense (Benefit) 418K USD
Net Income (Loss) Attributable to Parent -69.2M USD +59.7%
Earnings Per Share, Basic -0.56 USD/shares +62.2%
Earnings Per Share, Diluted -0.56 USD/shares +62.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 108M USD -38.3%
Cash, Cash Equivalents, and Short-term Investments 135M USD
Accounts Receivable, after Allowance for Credit Loss, Current 1M USD
Assets, Current 137M USD -36%
Property, Plant and Equipment, Net 2.2M USD -42.5%
Operating Lease, Right-of-Use Asset 4.58M USD -40.5%
Other Assets, Noncurrent 978K USD +105%
Assets 145M USD -36%
Accounts Payable, Current 4.33M USD -40.8%
Employee-related Liabilities, Current 7.34M USD -16.6%
Accrued Liabilities, Current 19M USD -13.4%
Contract with Customer, Liability, Current 22.2M USD -21.2%
Liabilities, Current 62.5M USD -1.85%
Contract with Customer, Liability, Noncurrent 79.5M USD -18.2%
Operating Lease, Liability, Noncurrent 1.29M USD -74.9%
Other Liabilities, Noncurrent 8K USD -85.5%
Liabilities 154M USD -18.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 10K USD -9.09%
Retained Earnings (Accumulated Deficit) -896M USD -8.37%
Stockholders' Equity Attributable to Parent -9.51M USD -126%
Liabilities and Equity 145M USD -36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32.7M USD -12.6%
Net Cash Provided by (Used in) Financing Activities 5.83M USD -73%
Net Cash Provided by (Used in) Investing Activities -72.5M USD -5297%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 116M shares -4.19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -99.4M USD -1540%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 108M USD -38.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 871K USD +10.1%
Deferred Tax Assets, Valuation Allowance 263M USD +9.76%
Deferred Tax Assets, Gross 264M USD +9.33%
Operating Lease, Liability 5.15M USD -38.7%
Payments to Acquire Property, Plant, and Equipment 132K USD -85.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -69.2M USD +59.7%
Lessee, Operating Lease, Liability, to be Paid 5.5M USD -42%
Operating Lease, Liability, Current 3.86M USD +18.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.31M USD -68.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.19M USD +5.33%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 349K USD -67.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.31M USD -68.7%
Deferred Tax Assets, Operating Loss Carryforwards 122M USD -3.78%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 423K USD +32.6%
Deferred Tax Assets, Net of Valuation Allowance 1.25M USD -39.8%
Share-based Payment Arrangement, Expense 16.5M USD -22.1%
Interest Expense 4.09M USD +14.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%